PubMed · 10888041
Split-course radiotherapy with or without concurrent or sequential chemotherapy in non-small cell lung cancer.
Abstract
In our department we designed a three-armed study to compare the effects of sequential and concurrent chemoradiotherapy in locally advanced non-small cell lung cancer. Each treatment arm consisted of 15 patients with histologically confirmed stage III non-small cell lung cancer. In group 1, the main treatment approach was split-course radiotherapy alone. In group 2, 6 mg/m2 of cisplatin was applied daily and concurrently with split-course radiotherapy. In group 3, two cycles of etoposide, ifosfamide, and cisplatin chemotherapy, which ended three weeks before split-course radiotherapy, was applied. Overall response rates were 40%, 66%, and 53% in groups 1, 2, and 3, respectively. Median survival was 10, 11, and 10 months for groups 1, 2, and 3 respectively. Results are discussed in the light of the literature.
Explore related subjects
Keep this discovery
Explore connections, maps & timelines
H C Ulutin, M Güden, K Oysul, S Sürenkök, Y Pak. Split-course radiotherapy with or without concurrent or sequential chemotherapy in non-small cell lung cancer.. https://pubmed.ncbi.nlm.nih.gov/10888041/
Cite the original work for its findings. Save a collection to share your selection of sources.